MYHERITAGE
26.1.2021 08:41:12 CET | Business Wire | Pressemeddelelse
MyHeritage , den førende globale tjeneste til at opdage din fortid og tage kontrol over din fremtid, annoncerede i dag udgivelsen af farvegendannelse til falmede farvefotos. En væsentlig forbedring af MyHeritages avancerede pakke af fotoværktøjer. Farvegendannelse genopliver de autentiske farver i falmede fotos med exceptionelle resultater.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20210125005981/da/
Farvegendannelse er ideel til gamle farvefotos fra 1950'erne til 1990'erne, hvor kemien af trykte fotos gemt i album ikke stod tidens prøve og fik farverne til at falme eller blive gule. Teknologien til farvegendannelse blev udelukkende licenseret fra DeOldify, skabt af eksperter inden for deep learning, Jason Antic og Dana Kelley, og blev integreret i MyHeritage. Det gendanner nøjagtigt et fotos originale farver og og gør på samme tid billedet skarpere. Farvegendannelse er en kraftfuld ny tilføjelse til MyHeritage In Color™ , virksomhedens flagskibsfotofunktion til farvelægning af sort-hvid fotos, som også blev udviklet af DeOldify og udelukkende licenseret af MyHeritage.
MyHeritage In Color™ og en anden AI-baseret funktion, MyHeritage Photo Enhancer , blev udgivet sidste år og er blevet brugt af forbrugere over 20 millioner gange. Begge er gået virale, har modtaget stor anerkendelse og inspireret en fornyet påskønnelse af historiske fotos blandt forbrugerne.
”I 2020 blev MyHeritage den bedste online destination for farvelægning, forbedring og deling af historiske fotos,” sagde Gilad Japhet, grundlægger og administrerende direktør for MyHeritage. ”Tilføjelsen af farvegendannelse til vores robuste serie af fotofunktioner, giver den utrolige mulighed for at bringe værdsatte barndomsminder tilbage i live og dele de smukt genoplivede fotos med vores familie og venner. Nostalgi bliver ikke bedre end dette!”
"Vi er begejstrede over, at vores banebrydende farvegendannelsesmodel vil blive nydt af fællesskabet som en del af MyHeritage In Color™", sagde Jason Antic og Dana Kelley, grundlæggere af DeOldify. "Det har været en stor indsats at skabe denne software, og vi kan ikke komme i tanke på en bedre partner til at bringe den på markedet end MyHeritage, et firma, der er defineret af innovation, og hvis mission er at gøre slægtshistorie mere tilgængelig for mennesker overalt i verden."
Integration i MyHeritage-platformen
Millioner af mennesker over hele verden bruger MyHeritage-platformen til at opdage deres slægtshistorie og bevare deres familiefotos digitalt. Med teknologier i verdensklasse til farvelægning og forbedring af fotos og med tilføjelsen af farvegendannelse, tilbyder MyHeritage banebrydende værktøjer, der giver nye perspektiver til slægtshistorie.
Farvegendannelse er tilgængelig på MyHeritage-platformen på nettet og i MyHeritages gratis mobilapp til iOS og Android. Mobilappen indeholder en indbygget scanner, så brugerne kan digitalisere familiefotos, der er gemt i fysiske album. Når et foto uploades til MyHeritage, afgører systemet automatisk, om fotoet er sort-hvidt (eller sepia) eller oprindeligt taget i farve. Fotos, der oprindeligt var sort-hvide, kan farvelægges, og de, der er taget i farve, kan få deres originale farver gendannet. Farvegendannede fotos kan let deles med familie og venner på Facebook, Twitter, WhatsApp og andre sociale medier. Gendannelse af farver ændrer ikke fotoet, men opretter en separat kopi på MyHeritage sammen med originalen.
MyHeritage In Color™ er en freemium-funktion på MyHeritage. Brugere kan gendanne farverne på 10 fotos gratis, hvorefter fortsat brug kræver et abonnement.
Om MyHeritage
MyHeritage er den førende globale platform til at opdage og udforske slægtshistorie. Med milliarder af historiske optegnelser og slægttræsprofiler og med sofistikerede matching-teknologier på tværs af alle dens aktiver, giver MyHeritage brugere mulighed for at opdage deres fortid og tage kontrol over deres fremtid. MyHeritage DNA blev lanceret i 2016 og er blevet en af verdens største forbruger-DNA-databaser med 4,7 millioner kunder. Siden 2020 er MyHeritage hjemsted for verdens bedste teknologier til forbedring og farvelægning af historiske fotos. MyHeritage er den mest populære tjeneste for DNA-tests og slægtshistorie i Europa. www.myheritage.dk
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210125005981/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum